MENU
Aim higher

LyMoDx

Development of novel non-invasive diagnostic tests to detect lymphomas

LyMoDx will deliver a novel in vitro diagnostic (IVD) test to detect cancer in blood. Cells release extracellular vesicles (EV) containing distinct RNA fingerprints into the blood; the EV-based RNA fingerprint for lymphoma will be technically validated, tested in a proof-of-concept study and offered as a diagnostic service to pharma, while being further developed into an in vitro diagnostic test (IVD). The consortium will perform full clinical studies directly after the project end.
Acronym: 
LyMoDx
Project ID: 
10 880
Ranking: 
60
Cut-off: 
6
Start date: 
01-01-2017
Project Duration: 
36months
Project costs: 
3 059 130.00€
Technological Area: 
Diagnostics, Diagnosis
Market Area: 
Diagnostic services